Keymed Biosciences Co. Ltd. has raised HK$982 million (US$125 million) in a placement on the Hong Kong Stock Exchange (HKEX:2162) to commercialize its IL-4Rα monoclonal antibody CM-310 branded as Stapokibart, and to advance its larger pipeline.

Biopharmas raising money in public or private financings, including: Actio, Acurx, Biomea Fusion, Cantargia, Cynaptec, Lobe Sciences, Nanocell, Polyactiva.

Jyong Biotech Ltd. raised $20 million from its Nasdaq debut June 17 to advance a pipeline of botanical drugs targeting male urinary disorders. The New Taipei City, Taiwan-headquartered company’s shares began trading under the ticker MENS, and closed at $10.11 apiece at the bell, up 34.80% from its listing price of $7.50 per share. Shares had kicked up to $15 at opening, reaching double its offering price.

Biopharmas raising money in public or private financings, including: Adial, Alzecure, Enliven, Fibrobiologics, Hemostemix, Jyong, Polypid, Recce, Sanofi, Theralase, Zyus.

Biopharmas raising money in public or private financings, including: Alzecure, Klotho.

For years, the biopharma industry has spent increasing amounts of money on R&D without improving success rates, leaving many executives searching for new, more predictable drug development paths.

Biopharmas raising money in public or private financings, including: Centivax, Enliven, Indaptus, Parallel Bio, Quince, Rebel.

Biopharmas raising money in public or private financings, including: ADC, Cabaletta, Citius, Enterome, Enyo, Insmed, Intensity, Preveceutical, Scinai.